Champions Oncology (CSBR) vs Fortress Biotech (FBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Champions Oncology (CSBR) has outperformed Fortress Biotech (FBIO) over the past year, losing 23.0% versus a loss of 28.2%. Over five years, CSBR leads with a -50.6% price change compared with -95.5% for FBIO. Fortress Biotech is the larger company by market cap ($69.7 million vs $69.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | FBIO |
|---|---|---|
| Share price | $4.98 | $2.09 |
| Market cap | $69.31M | $69.70M |
| 1-day change | +2.05% | +2.45% |
| YTD return | -27.93% | -42.90% |
| 1-year return | -23.03% | -28.18% |
| 5-year return | -50.60% | -95.48% |
| P/E ratio (TTM) | — | 0.76 |
| Forward P/E | 49.80 | — |
| EPS (TTM) | $-0.07 | $2.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $4.53 |
| 52-week low | $4.59 | $2.00 |
| Distance from 52-week high | -40.07% | -53.86% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +139.23% |
| Average volume | 11.33K | 495.05K |
| Shares outstanding | 13.92M | 33.35M |
| Employees | 214 | 78 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Healthcare · Biotechnology · 214 employees
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Healthcare · Biotechnology · 78 employees
CSBR vs FBIO FAQ
Which is bigger, Champions Oncology or Fortress Biotech?
Fortress Biotech (FBIO) is larger, with a market capitalization of $69.70M compared with $69.31M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or FBIO?
CSBR returned -23.03% over the past 12 months, compared with -28.18% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Fortress Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.